STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Emergent BioSolutions Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Emergent BioSolutions (EBS) received a Form 144 notice for a proposed sale of 17,801 common shares, showing an aggregate market value of $187,544.22. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as broker and identifies the NYSE as the exchange, with an approximate sale date of 11/10/2025.

The shares were acquired as restricted stock from the issuer on 10/02/2025, in the same amount of 17,801 shares. The notice also reports a prior sale in the last three months by Donald DeGolyer of 7,844 common shares on 08/12/2025 for $67,830.99. Shares outstanding are listed as 52,519,964.

Positive
  • None.
Negative
  • None.

Insights

Routine Form 144 for 17,801 EBS shares; neutral signal.

This notice records an affiliate’s intent to sell up to 17,801 common shares under Rule 144, with an aggregate market value of $187,544.22. The broker is Morgan Stanley Smith Barney LLC Executive Financial Services, and the filing cites an approximate sale date of 11/10/2025 on the NYSE.

The shares were acquired as restricted stock on 10/02/2025. The filing also notes a prior sale in the past three months by Donald DeGolyer of 7,844 shares for $67,830.99. Shares outstanding are listed as 52,519,964. These details are administrative and do not, by themselves, alter the investment thesis.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Latest SEC Filings

EBS Stock Data

519.42M
50.95M
2.84%
70.19%
16.33%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG